🔗 Visit the ClinicalTrials.gov page for NCT00706992
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. | Science | 2002 | 19.77 |
| 2 | Cancer immunotherapy: moving beyond current vaccines. | Nat Med | 2004 | 17.61 |
| 3 | Gene-engineered T cells for cancer therapy. | Nat Rev Cancer | 2013 | 2.07 |
| 4 | T cell clonal anergy. | Curr Opin Immunol | 1997 | 1.73 |
| 5 | Trial watch: Peptide vaccines in cancer therapy. | Oncoimmunology | 2012 | 1.17 |
| 6 | Trial Watch: Peptide vaccines in cancer therapy. | Oncoimmunology | 2013 | 1.04 |
| 7 | Genetically engineered T cells for the treatment of cancer. | J Intern Med | 2013 | 0.83 |
| 8 | Adjuvants: Classification, Modus Operandi, and Licensing. | J Immunol Res | 2016 | 0.81 |
| 9 | Targeting CD8+ T-cell tolerance for cancer immunotherapy. | Immunotherapy | 2014 | 0.81 |